Drug Res (Stuttg). 2021 Jul 14. Epub 2021 Jul 14. PMID: 34261152
Allicin Reduces 5-fluorouracil-resistance in Gastric Cancer Cells through Modulating MDR1, DKK1, and WNT5A Expression.
BACKGROUND & OBJECTIVE: 5-fluorouracil (5-FU) is approved for the treatment of gastric carcinoma (GC), but chemo-resistance limits the application of it for GC. Thus, the combination of 5-FU with adjuvants such as allicin may overcome multidrug resistance (MDR).METHODS: The anticancer effects of allicin, 5-FU, and allicin/5-FU on the 5-FU resistant MKN-45 cells were evaluated by MTT assay and DAPi staining. The expression of the P-glycoprotein (P-gp) and CD44 protein were determined using immunocytochemistry. We also quantified mRNA expression levels of(), andin the GC cells.RESULTS: Here, we found that the combination of allicin with 5-FU significantly increased apoptosis compared to 5-FU alone (